AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: SUTENT

First Posted Date: 2008-05-26

Last Posted Date: 2012-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 186

Registration Number: NCT00684645

Locations: 🇨🇿
Pfizer Investigational Site, Zlin, Czech Republic

Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

Completed

Conditions: Complicated Skin and Skin Structure Infections
Complicated Intra-abdominal Infections

Interventions: Drug: Tigecycline (Tygacil)

First Posted Date: 2008-05-23

Last Posted Date: 2011-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 621

Registration Number: NCT00683332

Locations: 🇵🇭
Pfizer Investigational Site, Manila, Philippines

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Phase 3

Completed

Conditions: Vasomotor Symptoms

Interventions: Drug: desvenlafaxine succinate (DVS) SR
Drug: Placebo

First Posted Date: 2008-05-23

Last Posted Date: 2011-08-17

Lead Sponsor: Pfizer

Target Recruit Count: 2186

Registration Number: NCT00683800

Locations: 🇨🇦
Pfizer Investigational Site, Quebec, Canada

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Phase 3

Completed

Conditions: Pain
Hallux Valgus

Interventions: Drug: valdecoxib
Drug: valdecoxib/placebo

First Posted Date: 2008-05-23

Last Posted Date: 2008-05-23

Lead Sponsor: Pfizer

Target Recruit Count: 450

Registration Number: NCT00683137

Locations: 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States

Study of Different Doses of a Novel Treatment for Onychomycosis

Phase 2

Completed

Conditions: Distal, Subungual Onychomycosis

Interventions: Drug: AN2690, 2.5%
Drug: AN2690, 5%
Drug: AN2690, 7.5%
Drug: Vehicle

First Posted Date: 2008-05-19

Last Posted Date: 2018-02-20

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00679770

Locations: 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸
Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC, San Antonio, Texas, United States

and more 1 locations

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

Phase 2

Completed

Conditions: Onychomycosis

Interventions: Drug: AN2690

First Posted Date: 2008-05-19

Last Posted Date: 2018-02-20

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT00680134

Locations: 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
DermResearch, Inc., Austin, Texas, United States

and more 4 locations

Study of Different Doses of a Novel Treatment for Onychomycosis

Phase 2

Completed

Conditions: Distal, Subungual Onychomycosis

Interventions: Drug: AN2690, 2.5%
Drug: AN2690, 5%
Drug: AN2690, 7.5%
Drug: AN2690 Solution Vehicle

First Posted Date: 2008-05-19

Last Posted Date: 2018-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 159

Registration Number: NCT00679965

Locations: 🇲🇽
Unidad de Investigación en Salud (UIS), Chihuahua, Mexico
🇲🇽
Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
🇲🇽
Instituto Dermatologico Jalisciense, Guadalajara, Mexico

and more 6 locations